GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » EV-to-Revenue

iX Biopharma (SGX:42C) EV-to-Revenue : 2.82 (As of Jun. 01, 2025)


View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, iX Biopharma's enterprise value is S$19.73 Mil. iX Biopharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was S$7.00 Mil. Therefore, iX Biopharma's EV-to-Revenue for today is 2.82.

The historical rank and industry rank for iX Biopharma's EV-to-Revenue or its related term are showing as below:

SGX:42C' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.76   Med: 19.88   Max: 262.08
Current: 2.81

During the past 11 years, the highest EV-to-Revenue of iX Biopharma was 262.08. The lowest was 2.76. And the median was 19.88.

SGX:42C's EV-to-Revenue is ranked worse than
55.29% of 973 companies
in the Drug Manufacturers industry
Industry Median: 2.43 vs SGX:42C: 2.81

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-01), iX Biopharma's stock price is S$0.019. iX Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was S$0.01. Therefore, iX Biopharma's PS Ratio for today is 2.38.


iX Biopharma EV-to-Revenue Historical Data

The historical data trend for iX Biopharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma EV-to-Revenue Chart

iX Biopharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 162.92 94.78 7.88 11.42 4.36

iX Biopharma Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 11.42 - 4.36 -

Competitive Comparison of iX Biopharma's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iX Biopharma's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where iX Biopharma's EV-to-Revenue falls into.


;
;

iX Biopharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

iX Biopharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=19.727/7
=2.82

iX Biopharma's current Enterprise Value is S$19.73 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. iX Biopharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was S$7.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iX Biopharma  (SGX:42C) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

iX Biopharma's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.019/0.008
=2.38

iX Biopharma's share price for today is S$0.019.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was S$0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iX Biopharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of iX Biopharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


iX Biopharma Business Description

Traded in Other Exchanges
N/A
Address
1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma Headlines

No Headlines